Mizuho raised the firm’s price target on Biogen (BIIB) to $207 from $177 and keeps an Outperform rating on the shares after slight adjustments to Mizuho’s assumptions in the company’s pipeline programs. The firm told investors that it continues to watch the Leqembi launch, and multiple clinical catalysts expected in 2026, primarily in the mid/2H26.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen: Balanced Risk/Reward Amid Alzheimer’s and Autoimmune Pipeline Uncertainty Supports Hold Rating
- Biogen price target raised to $180 from $153 at Citi
- Biogen assumed with a Neutral at UBS
- Biogen, Eisai say Leqembi BLA accepted in China
- Biogen announces publication of long term results from Phase 3 VALOR study